A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
ConditionMultiple System Atrophy
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age30-85
SponsorTiziana Life Sciences LTD
About this trial
A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)
Eligibility criteria
Qualifiers
Subjects with a clinical diagnosis of Clinically Established or Clinically Probable Multiple System Atrophy in accordance with 2022 MDS diagnostic criteria.
Age 30 to 85 years, at the time of signing the informed consent.
Stable dopaminergic treatment for at least 4 weeks before enrollment.
Adequate hematologic parameters without ongoing transfusion support: Hemoglobin (Hb) ≥ 9 g/dL; Platelets ≥ 100 x 109 cells/L.
Disqualifiers
Diagnosis or suspicion of other cause for Parkinsonism or a known alternate neurologic diagnosis.
Female patient who is pregnant, lactating, breastfeeding, or planning to become pregnant during study.
Individuals with claustrophobia who cannot tolerate the study procedures
Non-MRI-compatible implanted devices.
Trial design
Treatments tested in this trial
- Foralumab Nasal
Treatment groups
5 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov